Dr. Teresa C. Gentile, MD

Dr. Gentile practices at Upstate University Hospital in Syracuse, New York, part of State University of New York.

Dr. Gentile's NPI, 1902834245, was assigned on June 28, 2006. Dr. Gentile holds New York license 184891.

Dr. Gentile's primary practice is Upstate University Hospital, at 750 East Adams Street, Syracuse, NY 13210 in Onondaga County. The practice phone is (315) 473-4240.

Dr. Gentile's primary practice is Upstate University Hospital in Syracuse, New York, part of State University of New York. The medical group on file is Department of Medicine. Dmand AI also links Dr. Gentile to 1 more therapy and rehab clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gentile practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gentile's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Gentile is licensed in New York.

CMS data shows 490 Medicare services from Dr. Gentile across 6 procedure codes in 2024, for 123 Medicare patients. Medicare paid $40,911 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 123 Medicare patients who saw Dr. Gentile in 2024. The largest group is 65 to 74, with 43 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 28% are also on Medicaid. Their average risk score is 3.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gentile's median patient age at 62, with 46% women.

In 2024, Dr. Gentile wrote 17 Medicare Part D claims. Every claim was for a generic drug. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $89 in total drug cost. In 2018, CMS named 135 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Gentile for performance year 2024, reported as part of a group. Dr. Gentile accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 15 papers to Dr. Gentile, published from 2016 to 2023. 2020 was the busiest year, with 2. The most frequent topics are Antineoplastic Agents, Hematopoietic Stem Cell Transplantation and Multiple Myeloma. Dr. Gentile has published most often in J Investig Med High Impact Case Rep. Dr. Gentile's most frequent co-authors are Prashanth Ashok Kumar, Hani Hassoun, MD and David Duane Hurd, MD.

Dmand AI links Dr. Gentile to 8 clinical trials, 4 of them phase 3 studies. 6 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Burkitt Lymphoma. Academic and Community Cancer Research United sponsors the most, 3.

CMS Open Payments shows 6 general payments to Dr. Gentile from 4 drug and device companies from 2016 to 2020. Food and beverage make up the largest share, 92% of the total. Jazz Pharmaceuticals Inc. paid the most, $233. It also lists 3 research payments totaling $4,310 in 2021.